Nuveen Asset Management’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $10.3M | Sell |
352,498
-706,062
| -67% | -$20.5M | ﹤0.01% | 1588 |
|
|
2024
Q3 | $48.6M | Sell |
1,058,560
-150,140
| -12% | -$6.9M | 0.01% | 677 |
|
|
2024
Q2 | $49.4M | Buy |
1,208,700
+134,841
| +13% | +$5.51M | 0.01% | 626 |
|
|
2024
Q1 | $27.4M | Buy |
1,073,859
+583,265
| +119% | +$14.9M | 0.01% | 973 |
|
|
2023
Q4 | $4.44M | Buy |
490,594
+279,718
| +133% | +$2.53M | ﹤0.01% | 2048 |
|
|
2023
Q3 | $1.35M | Sell |
210,876
-1,664
| -0.8% | -$10.6K | ﹤0.01% | 2454 |
|
|
2023
Q2 | $2.36M | Buy |
212,540
+6,103
| +3% | +$67.7K | ﹤0.01% | 2264 |
|
|
2023
Q1 | $3.17M | Buy |
206,437
+28,617
| +16% | +$439K | ﹤0.01% | 2139 |
|
|
2022
Q4 | $3.95M | Buy |
177,820
+35,255
| +25% | +$782K | ﹤0.01% | 2050 |
|
|
2022
Q3 | $2.33M | Sell |
142,565
-40,897
| -22% | -$668K | ﹤0.01% | 2323 |
|
|
2022
Q2 | $2.67M | Buy |
183,462
+70,506
| +62% | +$1.02M | ﹤0.01% | 2291 |
|
|
2022
Q1 | $1.99M | Sell |
112,956
-1,238
| -1% | -$21.8K | ﹤0.01% | 2508 |
|
|
2021
Q4 | $2.69M | Sell |
114,194
-7,873
| -6% | -$186K | ﹤0.01% | 2422 |
|
|
2021
Q3 | $2.93M | Buy |
122,067
+4,007
| +3% | +$96K | ﹤0.01% | 2497 |
|
|
2021
Q2 | $2.92M | Buy |
118,060
+21,804
| +23% | +$539K | ﹤0.01% | 2534 |
|
|
2021
Q1 | $2.1M | Buy |
96,256
+31,104
| +48% | +$678K | ﹤0.01% | 2591 |
|
|
2020
Q4 | $1.66M | Buy |
65,152
+211
| +0.3% | +$5.38K | ﹤0.01% | 2596 |
|
|
2020
Q3 | $1.83M | Buy |
+64,941
| New | +$1.83M | ﹤0.01% | 2427 |
|